Statute Details
- Title: Health Products (Composition of Offences) Regulations 2011
- Act Code: HPA2007-S542-2011
- Type: Subsidiary Legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D)
- Enacting Authority: Health Sciences Authority (HSA), with Minister for Health’s approval
- Citation: S 542/2011
- Commencement: 3 October 2011
- Status / Current Version: Current version as at 27 March 2026
- Key Provisions: Regulation 1 (citation and commencement); Regulation 2 (compoundable offences); Regulation 3 (deletion/amendment to Medical Devices Regulations)
- Most Relevant Cross-Reference: Section 65 of the Health Products Act (composition/compounding of offences)
What Is This Legislation About?
The Health Products (Composition of Offences) Regulations 2011 (“Composition Regulations”) is a procedural enforcement instrument. In plain terms, it identifies which specific offences under the Health Products Act and its related regulations can be “compounded” (i.e., resolved by paying a composition sum) rather than being prosecuted in court.
In Singapore’s regulatory framework for health products—such as therapeutic products, medical devices, cosmetics, active ingredients, and products used in clinical trials—the Health Products Act sets out offences for contraventions. However, not every offence is necessarily suited to prosecution. The Composition Regulations operationalise a discretionary, administrative pathway: the Chief Executive of the HSA (or an authorised officer) may compound certain offences under section 65 of the Act.
The Regulations also reflect the evolving regulatory landscape. Over time, amendments have expanded the list of compoundable offences to cover newer regulatory regimes (for example, active ingredients and medical devices updates) and to adjust the scope of compounding to match enforcement priorities.
What Are the Key Provisions?
Regulation 1 (Citation and commencement) confirms the legal identity and timing of the instrument. It provides that the Regulations may be cited as the Health Products (Composition of Offences) Regulations 2011 and that they came into operation on 3 October 2011. For practitioners, this matters when assessing whether a compounding pathway was available at the time of an alleged contravention.
Regulation 2 (Compoundable offences) is the core provision. It states that the following offences may be compounded in accordance with section 65 of the Health Products Act by the Chief Executive or an officer authorised in writing by the Chief Executive.
The Regulation then enumerates categories of offences by reference to specific sections of the Act and specific regulations across multiple subsidiary instruments. The list is detailed and granular, often limiting compounding to particular sub-paragraphs or contraventions. This drafting technique is important: it signals that compounding is not an “all offences” option; it is limited to those offences that the HSA and the Minister have determined are appropriate for administrative resolution.
(a) Offences under the Health Products Act
Regulation 2(a) lists offences under various sections of the Act (for example, offences under sections 12(6)(a), 13(6)(a), 14(4), 15(2), 16(2)(a), 17(3), 18(2), 19(2), 20(3), 21(3), 23(3)(a), 35(4), 36(5), 40(3), 41(2), 42(5)(a), 43(3), 44(3)(a), 49(5)(e), (9) or (11), 50, and 66(4)).
Although the extract provided does not reproduce the substantive content of each Act offence, the legal effect is clear: if an alleged conduct falls within one of these enumerated statutory offences, the HSA may offer compounding instead of prosecution, subject to the conditions and process in section 65 of the Act.
(b) Offences under the Health Products (Active Ingredients) Regulations 2023
Regulation 2(aa) (inserted by amendment S 832/2023 with effect from 18 December 2023) adds offences under section 47(4) of the Act “relating to a contravention of a regulation” in the Health Products (Active Ingredients) Regulations 2023, but with a notable carve-out: it excludes offences relating to contraventions of regulation 4 or 5 of those Active Ingredients Regulations.
For practitioners, this carve-out is a key interpretive point. It indicates that certain regulatory requirements—likely those considered more serious or higher-risk—are not suitable for compounding. When advising clients, counsel should therefore check both (i) whether the offence is within the compoundable list and (ii) whether the particular contravened regulation falls within the excluded provisions.
(c) Offences under cosmetics, medical devices, therapeutic products, and other product regimes
Regulation 2(b) includes offences under specific provisions of the Health Products (Cosmetic Products – ASEAN Cosmetic Directive) Regulations 2007 (notably regulation 4(3), 10(3), and 11(4)(a)).
Regulation 2(c) covers offences under the Health Products (Medical Devices) Regulations 2010, but only for specified sub-regulations (e.g., regulation 13A(3), 31(5), 32(2), 36A(5), 37, 38(3), 39(3), 39A(3), 39B(3), 40(2), 41(3), 43(2), 44(4), 45(3), 46(4), 47(3), 48(6) or (7)(b), and 49(5) or (6)(b)).
Similarly, Regulation 2(d) lists compoundable offences under the Health Products (Therapeutic Products) Regulations 2016 (with specified sub-regulations), and Regulation 2(e) includes an offence under regulation 7(5) of the Health Products (Licensing of Retail Pharmacies) Regulations 2016.
Regulation 2(f) addresses advertising-related offences: it includes an offence under regulation 15(2) of the Health Products (Advertisement of Therapeutic Products) Regulations 2016, which was renamed as the Health Products (Advertisement of Specified Health Products) Regulations 2016 from 1 March 2021. This renaming is legally significant because it affects how practitioners locate the relevant regulatory text, even though the compounding provision refers to the offence provision.
(d) Clinical trials and clinical research materials
Regulation 2(g) is particularly extensive. It provides that an offence under regulation 29(1)(a) of the Health Products (Clinical Trials) Regulations 2016 may be compounded, but only in respect of contraventions of a long list of specific regulations within the Clinical Trials Regulations (including regulations 4(4) or (6), 5(1)–(4) and (6), 6, 7(2), 8(1), 9(1), 10(1), (2), (4) or (6), and many others).
This structure suggests that regulation 29(1)(a) is a “catch” offence tied to contraventions of specified duties. The compounding list then narrows which underlying contraventions are eligible. Practically, this means that the same offence provision may be compoundable or non-compoundable depending on which specific duty was breached.
Regulation 2(h) similarly covers offences under regulation 24(1)(a) of the Health Products (Therapeutic Products as Clinical Research Materials) Regulations 2016, renamed as the Health Products (Clinical Research Materials) Regulations 2016 from 1 March 2021.
(e) Oral dental gums, cell/tissue/gene therapy products
Regulation 2(i) includes offences under the Health Products (Oral Dental Gums) Regulations 2016 for specified sub-regulations (e.g., regulation 17(3), 19(5), 23, 24(5) or (6)(a), 25(3), 26(3) or 27(2)).
Regulation 2(j) includes offences under the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 for specified sub-regulations (e.g., regulation 28(4), 32(3), 33(4), 34(5), 35(3), 44, 45(6) or (7)(b), 46(2), 48(4) or (5)(b), 49(2), 50(3), 51(2) or 56(3)).
Regulation 3 (Amendment of Health Products (Medical Devices) Regulations 2010) deletes regulation 51 of the Medical Devices Regulations 2010. While the extract does not state the content of regulation 51, the deletion indicates that the compounding framework required a consequential amendment—likely to remove an obsolete or overlapping provision. For practitioners, this is a reminder to check whether deleted provisions affected compounding eligibility or enforcement mechanics at the time of earlier versions.
How Is This Legislation Structured?
The Regulations are short and focused, consisting of three regulations:
Regulation 1 sets out citation and commencement. Regulation 2 contains the operative list of offences that may be compounded, organised by reference to the Health Products Act and multiple subsidiary regulations. Regulation 3 makes a consequential deletion to the Medical Devices Regulations 2010.
There are no “Parts” in the instrument as presented; the structure is essentially a single compounding schedule embedded within Regulation 2.
Who Does This Legislation Apply To?
The Regulations apply to persons who may commit offences under the Health Products Act and its related subsidiary regulations—typically manufacturers, importers, distributors, retailers, clinical trial sponsors/investigators, and advertisers/marketing actors within the health products ecosystem. The compounding mechanism is available where the alleged conduct falls within the enumerated offences.
Importantly, the Regulations do not create new substantive offences. Instead, they determine which existing offences are eligible for administrative resolution under section 65 of the Act. Therefore, applicability depends on the underlying offence and the specific contravention (including any carve-outs such as those excluding contraventions of Active Ingredients Regulations 4 or 5).
Why Is This Legislation Important?
For practitioners, the practical value of the Composition Regulations lies in risk management and enforcement strategy. Compounding can be faster and less resource-intensive than prosecution, and it may allow regulated entities to resolve compliance breaches without the uncertainty and reputational impact of court proceedings.
However, compounding is not automatic. The Regulations only identify eligible offences; the decision to compound, the composition sum, and procedural requirements are governed by section 65 of the Health Products Act and the HSA’s administrative processes. Counsel should therefore treat the Composition Regulations as a threshold eligibility document, not as a guarantee of compounding.
The detailed enumeration and sub-regulation specificity also matter for legal advice. When assessing whether a client’s conduct is compoundable, lawyers must map the alleged facts to the exact offence provision and, where relevant, to the exact contravened regulation within a broader offence framework (as seen in the Clinical Trials Regulations and Active Ingredients carve-outs). This is particularly important for multi-faceted compliance matters where several regulatory duties may be implicated.
Related Legislation
- Health Products Act (Cap. 122D) — in particular, section 65 (composition/compounding of offences) and the offence-creating provisions referenced in Regulation 2
- Health Products (Medical Devices) Regulations 2010 (G.N. No. S 436/2010)
- Health Products (Active Ingredients) Regulations 2023 (G.N. No. S 831/2023)
- Health Products (Cosmetic Products – ASEAN Cosmetic Directive) Regulations 2007 (G.N. No. S 683/2007)
- Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016)
- Health Products (Licensing of Retail Pharmacies) Regulations 2016 (G.N. No. S 330/2016)
- Health Products (Advertisement of Therapeutic Products) Regulations 2016 / Health Products (Advertisement of Specified Health Products) Regulations 2016 (G.N. No. S 333/2016)
- Health Products (Clinical Trials) Regulations 2016 (G.N. No. S 331/2016)
- Health Products (Clinical Research Materials) Regulations 2016 (G.N. No. S 332/2016)
- Health Products (Oral Dental Gums) Regulations 2016 (G.N. No. S 539/2016)
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021)
Source Documents
This article provides an overview of the Health Products (Composition of Offences) Regulations 2011 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.